Midatech Pharma Plc (MTPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Market Overview

Summary

Midatech Pharma Plc (Midatech) is a pharmaceutical company that develops and commercializes products in oncology and other therapeutic areas. The company's products include gelclair, oravig, soltamox and zuplenz. It conducts research and development programs in the areas of oncology, autoimmune diseases, pipeline, Q-octreotide, opsisporin, HCC, glioblastoma and diabetes vaccine. Midatech's products are used in treatment of diabetes; rare cancers including brain, ovarian, liver and pancreatic cancer and neurological and ophthalmologic conditions. It collaborates with universities, and specialty and major pharmaceutical companies to develop its platform technologies. The company operates through its manufacturing facility in Bilbao, and research facility in Cardiff. Midatech is headquartered in Abingdon, the UK.

Midatech Pharma Plc (MTPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Scope

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Midatech Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Midatech Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 11

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Midatech Pharma Acquires Zuplenz from Galena Biopharma for up to USD29.7 Million 14

Venture Financing 15

Q Chip Raises USD 3 Million Venture Financing 15

Private Equity 16

Kanwa Holdings to Acquire Midatech Pharma US from Midatech Pharma 16

Partnerships 18

Midatech Pharma US Enters into Co-Promotion Agreement with Bausch Health 18

Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 19

Midatech Pharma Enters into Agreement with Ophthotech 20

Midatech Pharma Enters into Agreement with Dana-Farber Cancer Institute 21

DARA BioSciences Enters into Commercialization Agreement with Onxeo 22

DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 23

Midatech Enters into Research Collaboration Agreement with Middlesex University 24

Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 25

Midatech Enters into Research and Collaboration Agreement with The Open University 26

Midatech Enters Into Joint Venture With MonoSol Rx 27

Licensing Agreements 28

Midatech Pharma Enters Into Licensing Agreement with Novartis 28

Emergex Vaccines Enters into Licensing Agreement with Midatech Pharma 29

Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 30

DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 31

DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 32

Equity Offering 33

Midatech Pharma Raises USD8 Million in Private Placement of Shares 33

Midatech Pharma to Raise USD2.7 Million in Rights Offering of Shares 34

Midatech Pharma Raises USD19.8 Million in Private Placement of Shares 35

Midatech Pharma Raises USD50 Million in IPO 36

Dara BioSciences Raises USD12.5 Million in Public Offering of Units 38

Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To USD 32.5 Million 39

Dara BioSciences Raises USD6 Million in Private Placement Of Shares 40

Dara BioSciences Completes Private Placement Of Shares For USD 2.6 Million 41

Dara BioSciences Announces Public Offering Of Common Stock For USD 2.7 Million 42

Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For USD 2.6 Million 43

Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For USD 0.3 Million 44

DARA BioSciences Completes Public Offering Of Units For USD 10 Million 45

DARA BioSciences Completes Private Placement Of Preferred Stock For USD 1.7 Million 47

Acquisition 49

Midatech Pharma Acquires Dara BioSciences 49

Midatech Pharma Acquires Q Chip 51

DARA BioSciences Acquires Oncogenerix 52

Midatech Pharma Plc-Key Competitors 53

Midatech Pharma Plc-Key Employees 54

Midatech Pharma Plc-Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Joint Venture 55

Recent Developments 56

Strategy And Business Planning 56

Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility 56

Financial Announcements 57

Apr 23, 2018: Midatech Pharma: Audited financial results for the year ended 31 December 2017 57

Sep 28, 2017: Midatech Pharma: Interim results for the six months ended 30 June 2017 63

Apr 04, 2017: Midatech Pharma Announces Audited financial results for the year ended 31 December 2016 67

Jan 20, 2017: Midatech Pharma Provides Trading Update 68

Corporate Communications 69

Jun 01, 2018: Midatech Pharma: Board change 69

Mar 15, 2018: Midatech announces changes in Senior Management Team 70

Government and Public Interest 71

Nov 23, 2017: Midatech secures manufacturing certification from Spanish regulatory authority 71

Product News 72

May 22, 2017: Midatech announces progress update on brain cancer therapies 72

01/16/2018: Midatech and UCSF receive IND approval for DIPG treatment MTX110 73

Clinical Trials 74

May 25, 2018: Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer 74

Jul 26, 2017: Midatech Pharma: Completion of pre-clinical liver cancer programme 75

Other Significant Developments 76

Jul 25, 2018: Midatech Pharma: Trading update 76

Appendix 77

Methodology 77

About GlobalData 77

Contact Us 77

Disclaimer 77


List Of Figure

List of Figures

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Midatech Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Midatech Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Midatech Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 10

Midatech Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 11

Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Midatech Pharma Acquires Zuplenz from Galena Biopharma for up to USD29.7 Million 14

Q Chip Raises USD 3 Million Venture Financing 15

Kanwa Holdings to Acquire Midatech Pharma US from Midatech Pharma 16

Midatech Pharma US Enters into Co-Promotion Agreement with Bausch Health 18

Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 19

Midatech Pharma Enters into Agreement with Ophthotech 20

Midatech Pharma Enters into Agreement with Dana-Farber Cancer Institute 21

DARA BioSciences Enters into Commercialization Agreement with Onxeo 22

DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 23

Midatech Enters into Research Collaboration Agreement with Middlesex University 24

Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 25

Midatech Enters into Research and Collaboration Agreement with The Open University 26

Midatech Enters Into Joint Venture With MonoSol Rx 27

Midatech Pharma Enters Into Licensing Agreement with Novartis 28

Emergex Vaccines Enters into Licensing Agreement with Midatech Pharma 29

Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 30

DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 31

DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 32

Midatech Pharma Raises USD8 Million in Private Placement of Shares 33

Midatech Pharma to Raise USD2.7 Million in Rights Offering of Shares 34

Midatech Pharma Raises USD19.8 Million in Private Placement of Shares 35

Midatech Pharma Raises USD50 Million in IPO 36

Dara BioSciences Raises USD12.5 Million in Public Offering of Units 38

Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To USD 32.5 Million 39

Dara BioSciences Raises USD6 Million in Private Placement Of Shares 40

Dara BioSciences Completes Private Placement Of Shares For USD 2.6 Million 41

Dara BioSciences Announces Public Offering Of Common Stock For USD 2.7 Million 42

Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For USD 2.6 Million 43

Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For USD 0.3 Million 44

DARA BioSciences Completes Public Offering Of Units For USD 10 Million 45

DARA BioSciences Completes Private Placement Of Preferred Stock For USD 1.7 Million 47

Midatech Pharma Acquires Dara BioSciences 49

Midatech Pharma Acquires Q Chip 51

DARA BioSciences Acquires Oncogenerix 52

Midatech Pharma Plc, Key Competitors 53

Midatech Pharma Plc, Key Employees 54

Midatech Pharma Plc, Subsidiaries 55

Midatech Pharma Plc, Joint Venture 55

You can also purchase parts of this report. Do you want to check out a section wise price list?
Thank You for submiting the form our team will reach you withing next 24 hours.
85% of our clients seek customized reports. How do you wish us to custom yours?


Products

Products

Midatech Pharma Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Testimonial